Application Nr Approved Date Route Status External Links
ANDA202095 2016-06-06 Oral RX Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Levetiracetam Extended-Release Tablets Is Indicated As Adjunctive Therapy In The Treatment Of Partial Onset Seizures In Patients 12 Years Of Age And Older With Epilepsy. Levetiracetam Extended-Release Tablets Is Indicated For Adjunctive Therapy In The Treatment Of Partial Onset Seizures In Patients 12 Years Of Age And Older With Epilepsy (1).

All Formulated Excipients (6 Total)

Name Structure Kind Function Status
1. Silicon Dioxide SILICON DIOXIDE Unresolved AC-Anticaking agent , MISC-Miscellaneous , STAB-Stabilizer GRAS-Generally recognized as safe.
2. Ethylcelluloses ETHYLCELLULOSES Unresolved
3. Glyceryl Dibehenate GLYCERYL DIBEHENATE Unresolved
4. Lactose Monohydrate LACTOSE MONOHYDRATE Molecular
5. Povidone K90 POVIDONE K90 Unresolved
6. Magnesium Stearate MAGNESIUM STEARATE Molecular AF-Antifoaming (or defoaming) agent , MISC-Miscellaneous REG-Food additives for which a petition has been filed and a regulation issued.

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Levetiracetam LEVETIRACETAM ZINC1547851

Comments